Evidence map›Paper›PMID 30587978›Full record

ArticleInternational journal of nanomedicine2018

Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells.

Barbara Strojny, Ewa Sawosz, Marta Grodzik, Sławomir Jaworski, Jarosław Szczepaniak, Malwina Sosnowska, Mateusz Wierzbicki, Marta Kutwin, Sylwia Orlińska, André Chwalibog

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Barbara StrojnyDivision of Nanobiotechnology, Warsaw University of Life Sciences, Warsaw, Poland.
Ewa SawoszDivision of Nanobiotechnology, Warsaw University of Life Sciences, Warsaw, Poland.
Marta GrodzikDivision of Nanobiotechnology, Warsaw University of Life Sciences, Warsaw, Poland.
Sławomir JaworskiDivision of Nanobiotechnology, Warsaw University of Life Sciences, Warsaw, Poland.
Jarosław SzczepaniakDivision of Nanobiotechnology, Warsaw University of Life Sciences, Warsaw, Poland.
Malwina SosnowskaDivision of Nanobiotechnology, Warsaw University of Life Sciences, Warsaw, Poland.
Mateusz WierzbickiDivision of Nanobiotechnology, Warsaw University of Life Sciences, Warsaw, Poland.
Marta KutwinDivision of Nanobiotechnology, Warsaw University of Life Sciences, Warsaw, Poland.
Sylwia OrlińskaDivision of Nanobiotechnology, Warsaw University of Life Sciences, Warsaw, Poland.
André ChwalibogDepartment of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark, ach@sund.ku.dk.
Warsaw University of Life Sciences · PLUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectiveCurrently, carbon nanostructures are vastly explored materials with potential for future employment in biomedicine. The possibility of employment of diamond nanoparticles (DN), graphene oxide (GO) or graphite nanoparticles (GN) for in vivo applications raises a question of their safety. Even though they do not induce a direct toxic effect, due to their unique properties, they can still interact with molecular pathways. The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver.

methodsDose-dependent effect of the DN, GO and GN nanostructures on the catalytic activity of CYPs was examined using microsome-based model. Cytotoxicity of DN, GO and GN, as well as the influence of the nanostructures on mRNA expression of CYP genes and CYP-associated receptor genes were studied in vitro using HepG2 and HepaRG cell lines.

resultsAll three nanostructures interacted with the CYP enzymes and inhibited their catalytic activity in microsomal-based models. CYP gene expression at the mRNA level was also downregulated in HepG2 and HepaRG cell lines. Among the three nanostructures, GO showed the most significant influence on the enzymes, while DN was the most inert.

conclusionOur findings revealed that DN, GO and GN might interfere with xenobiotic and drug metabolism in the liver by interactions with CYP isoenzymes responsible for the process. Such results should be considered if DN, GO and GN are used in medical applications.

Indexed as

Cell SurvivalCytochrome P-450 CYP1A2Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDiamondDown-RegulationFluorescenceGraphiteHepatocytesHep G2 CellsHumansHydrodynamicsIsoenzymesLiverCytochrome P-450 CYP1A2Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDiamondgraphene oxideGraphiteIsoenzymescarbon nanostructurescytochrome P450livermicrosomesnanoparticles

Identifiers

PMID30587978
PMCPMC6300366
OpenAlexW2905161171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.